FDA Approves Lurbinectedin in Combination with Atezolizumab or Atezolizumab and Hyaluronidase-tqjs for Extensive Stage SCLC By Ogkologos - October 16, 2025 153 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the IMforte study Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR AI Model Identifies How Every Country Can Improve Its Cancer Outcomes January 14, 2026 ‘Inside Edition’ Anchor Thanks Viewer For Pointing Out Lump That Turned... April 24, 2019 Exercise of Any Intensity Found to Provide Similar Benefits in Cancer... February 10, 2021 8-Year-Old Cancer Survivor Breaks National Record for Girl Scout Cookie Sales April 1, 2021 Load more HOT NEWS EMA Recommends Extension of Indications for Daratumumab Daughter And Her Terminally Ill Dad Go On Bucket List Adventures... TAT 2021 Honorary Award: A Recognition in Cancer Drug Development to... EMA Recommends Granting a Marketing Authorisation for Vorasidenib
